γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: Results from 2 phase I clinical trials of SJG-136 (SG2000)

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 721-730

  Wu, Jenny ^a   Clingen, Peter H ^a   Spanswick, Victoria J ^a   Mellinas Gomez, Maria ^a   Meyer, Tim ^a   Puzanov, Igor ^b   Jodrell, Duncan ^c   Hochhauser, Daniel ^a   Hartley, John A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE H2AX; HISTONE H2AX GAMMA; SJG 136; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DRUG DOSE ESCALATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR BIOPSY;

BENZODIAZEPINONES; COMET ASSAY; DNA DAMAGE; FIBROBLASTS; HISTONES; HUMANS; LYMPHOCYTES; PHARMACOGENETICS; PYRROLES;

EID: 84873388790     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2529     Document Type: Article

References (37)

1. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
2. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. Proc Natl Acad Sci U S A 2003;100:5057-62.
3. Fillingham J, Keogh MC, Krogan NJ. GammaH2AX and its role in DNA double strand break repair. Biochem Cell Biol 2006;84:568-77.
4. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, Nbs1 in response to replication-dependent DNA double strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
5. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma 2009;118:683-92.
6. Redon CE, Nakamura AJ, Zhang Y-W, Ji JJ, Bonner WM, Kinders RJ, et al. Histone gH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010;16:4532-42.
7. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004;58:331-5.
8. Klokov D, MacPhail SM, Banath JP, Bryne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 2006;80:223-9.
9. Banuelos CA, Banath JP, Kim J-Y, Aquino-Parsons C, Olive PL. gH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009;15:3344-53.
10. Clingen PH, Wu JY-H, Miller J, Mistry N, Chin F, Wynne P, et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008;76:19-27.
11. Huang X, Okafuji M, Traganos F, Luther E, Holden E, Darzynkiewicz Z. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry 2004;58:99-110.
12. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-87.
13. Mogi S, Oh DH. Gamma-H2AX formation in response to interstrand crosslinks requires XPF in human cells. DNA Repair 2006;5:731-40.
14. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, et al. Design synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 2001;44:737-8.
15. Martin C, Ellis T, McGurk CJ, Jenkins TC, Hartley JA, Waring MJ, et al. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Biochem 2005;44:4135-47.
16. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9.
17. Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 2: efficacy evaluations. Cancer Res 2004;64:6700-6.
18. Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, et al. Phase I study of a sequence selective minor groove DNA binding agent (SJG-136) with pharmacokinetic and pharmacodynamic measurements in patients with advanced solid tumors. Clin Cancer Res 2009;15:2140-7.
19. Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, et al. Phase I, pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 2011;17;3794-802.
20. Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, et al. A phase I trial of SJG-136 (NSC694501) in advanced solid tumors. Cancer Chemother Pharmacol 2010;65:833-8.
21. Spanswick VJ, Hartley JM, Hartley JA. Measurement of DNA interstrand crosslinking in individual cells using the single cell gel electrophoresis (comet) assay. In: Fox K. (ed). Methods in molecular biology, Vol 613 Drug-DNA Interaction Protocols, 2nd Edn. Totowa, NJ: Humana Press; 2010. p. 267-82.
22. Corrie GG, Shaw J, Spanswick VJ, Sehmbi R, Jonson A, Mayer A, et al. Phase I trial combining gemcitabine and treosulphan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005;92: 1997-2003.
23. Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et. al. A phase I study of single administration of antibody-directed enzyme prodrug therapy (ADEPT) with the recombinant anti-CEA antibodyenzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 2006;12:6509-16.
24. Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, et al. Quinone oxidoreductase-2 mediated prodrug cancer therapy. Sci Trans Med 2010;2;40ra50.
25. Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, et al. Carboplatin and gemcitabine in patients with 'platinum-resistant' ovarian cancer: demonstration of inhibition of carboplatin-induced DNA interstrand crosslink repair by gemcitabine. Clin Cancer Res 2010;16:4899-905.
26. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair intumour and normal cells measure dusing the "comet" assay. Radiation Res 1990;122:86-94.
27. Arnould S, Spanswick VJ, Macpherson JS, Hartley JA, Thurston DE, Jodrell DI, et al. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signalling. Mol Cancer Ther 2006;5:1602-9.
28. Rahman KM, Thompson AS, James CH, Narayanaswamy M, Thurston DE. The pyrrolodiazepine dimer SJG-136 forms sequencedependent intrastrand cross-links and monoalkylated adducts in addition to interstrand cross-links. J Am Chem Soc 2009;131: 13756-66.
29. Clingen PH, De Silva IU, McHugh PJ, Ghadessy FJ, Tilby MJ, Thurston DE, et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 2005;33:3283-91.
30. Hartley JA. Alkylating agents. In: Souhami RL, Tannock I, Hohenberger P, Horiot JC, editors. Oxford Textbook of Oncology 2nd Edn. Oxford University Press, Oxford, UK. 2001 p639-54.
31. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-90.
32. Banath JP, MacPhail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004;64:7144-9.
33. Sedelnikova OA, Bonner WM. gH2AX in cancer cells: a potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006;5:2909-13.
34. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010;16:1073-83.
35. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762-9.
36. Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase I trial of the farnsyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009;113:4824-5.
37. Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, et al. Development of a validated immunofluorescence assay for g-H2AX as a pharmacodynamics marker of topoisomerase I inhibitor activity. Clin Cancer Res 2010;16:5447-57.